Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
solid tumors with NTRK gene fusion |
| gptkbp:category |
targeted therapy
oncology drug |
| gptkbp:developedBy |
gptkb:Loxo_Oncology
gptkb:Ignyta |
| gptkbp:example |
gptkb:entrectinib
gptkb:larotrectinib |
| https://www.w3.org/2000/01/rdf-schema#label |
TRK inhibitors
|
| gptkbp:mechanismOfAction |
inhibit TRK proteins
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
dizziness fatigue |
| gptkbp:target |
NTRK gene fusions
tropomyosin receptor kinases |
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:ETV6-NTRK3_fusion
gptkb:TRK_B gptkb:NTRK3_gene gptkb:TRK_(gene,_NTRK1,_NTRK2,_NTRK3) |
| gptkbp:bfsLayer |
8
|